中国呼吸与危重监护杂志

中国呼吸与危重监护杂志

血清甲状腺激素水平对慢性阻塞性肺疾病急性加重患者预后评估价值研究

查看全文

目的研究无原发甲状腺疾病的慢性阻塞性肺疾病(简称慢阻肺)急性加重患者血清甲状腺激素水平与疾病预后的关系,并探讨血清甲状腺激素水平对慢阻肺急性加重患者预后评估的价值。方法回顾性分析 2013 年 1 月至 2017 年 11 月于北京积水潭医院呼吸与危重症医学科因慢阻肺急性加重住院的患者 239 例,男 149 例,女 90 例,年龄 42~92 岁,平均(77.7±8.9)岁。入院时采用电化学发光法测定血清甲状腺激素水平[总甲状腺素(TT4)、总三碘甲状腺原氨酸(TT3)、促甲状腺素(TSH)、游离甲状腺素(FT4)、游离三碘甲状腺原氨酸(FT3)]。根据预后分为治疗好转组和死亡组。进行两组间血清甲状腺激素水平的比较,以及血清甲状腺激素水平与疾病转归的相关性分析,采用受试者工作特征(ROC)曲线评估不同甲状腺激素指标对于慢阻肺急性加重患者预后的判断价值,并确定慢阻肺急性加重患者死亡发生风险的甲状腺激素最佳预测值。结果慢阻肺急性加重治疗好转组血清 TT4、TT3、FT4、FT3 明显高于死亡组[TT4:(89.35±21.45)nmol/L 比(76.84±21.33)nmol/L;TT3:(1.05±0.34)nmol/L 比(0.72±0.19)nmol/L;FT4:(16.17±2.91)pmol/L 比(14.45±2.85)pmol/L;FT3:(3.06±0.81)pmol/L 比(2.24±0.72)pmol/L,P<0.05]。两组间血清 TSH 差异无统计学意义[0.98(0.54~1.83)mIU/L 比 0.57(0.31~1.84)mIU/L,P>0.05]。Spearman 相关分析显示,慢阻肺急性加重患者血清 TT4、TT3、FT4、FT3 与死亡发生呈显著相关(r 值分别为 0.226、0.417、0.220、0.387,均 P<0.05),血清 TSH 与死亡发生无显著相关性(P>0.05)。拟合不同甲状腺激素指标(TT4、TT3、TSH、FT4、FT3)与慢阻肺急性加重患者发生死亡关系的 ROC 曲线,曲线下面积分别为 0.659、0.793、0.588、0.655、0.772。对于预测慢阻肺急性加重患者死亡发生风险,TT3 优于其他甲状腺激素指标。当血清 TT3=0.85 nmol/L 时,Youden 指数最大(0.486),敏感性 70.2%,特异性 78.3%,为慢阻肺急性加重患者死亡发生风险的 TT3 最佳预测值。结论慢阻肺急性加重患者血清甲状腺激素水平与预后密切相关,对慢阻肺急性加重患者预后评估具有一定的价值。

ObjectiveTo investigate the association between serum thyroid hormone levels and prognosis for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) without thyroid disease, and explore the prognostic value of serum thyroid hormone levels for patients with AECOPD.MethodsThe clinical data of 239 hospitalized cases of AECOPD [149 males, 90 females, aged 42-92 (77.7±8.9) years] from January 2013 to November 2017 were retrospectively analyzed. Serum thyroid hormone levels including total tetraiodothyronin (TT4), total triiodothyronin (TT3), thyroid stimulating hormone (TSH), free tetraiodothyronin (FT4) and free triiodothyronin (FT3) were measured by chemiluminescence immunoassay. All patients were divided into a survival group and a death group according to the prognosis. Serum thyroid hormone levels were compared between two groups. Correlations of serum thyroid hormone levels with the occurrence of death in AECOPD patients were analyzed. The prognostic value of serum thyroid hormone levels for AECOPD patients was explored by receiveroperating characteristic (ROC) curve analysis. And the best cut-off value of serum thyroid hormone level in predicting the risk of death was calculated.ResultsSerum TT4, TT3, FT4 and FT3 levels in the survival group were significantly higher than those in the death group [TT4: (89.35±21.45) nmol/L vs. (76.84±21.33) nmol/L; TT3: (1.05±0.34) nmol/L vs. (0.72±0.19) nmol/L; FT4: (16.17±2.91) pmol/L vs. (14.45±2.85) pmol/L; FT3: (3.06±0.81) pmol/L vs. (2.24±0.72) pmol/L; all P<0.05]. The differences of serum TSH level between two groups were not statistically significant [0.98 (0.54-1.83)vs. 0.57 (0.31-1.84), P>0.05]. Spearman correlation analysis showed that serum TT4, TT3, FT4 and FT3 levels were significant correlated with the occurrence of death (r values were 0.226, 0.417, 0.220, 0.387, respectively, P<0.05). And there was no significant correlation between serum TSH level and the occurrence of death (P>0.05). ROC curve analysis was done between serum thyroid hormone levels (TT4, TT3, TSH, FT4 and FT3) and the occurrence of death in the AECOPD patients. The areas under ROC curve were 0.659, 0.793, 0.588, 0.655 and 0.772, respectively. Serum TT3 was the best indicator for predicting the occurrence of death. When serum TT3 level was 0.85nmol/L, the Youden index was the highest (0.486), with a sensitivity of 70.2%, and a specificity of 78.3%. It was the best cut-offl value of serum TT3 to predict the risk of death in AECOPD patients.ConculsionsSerum thyroid hormone levels are significant associated with the prognostic for AECOPD patients. There is certain value of serum thyroid hormone levels in prognostic evaluation of AECOPD patients.

关键词: 慢性阻塞性肺疾病; 急性加重; 血清甲状腺激素; 预后

Key words: Chronic obstructive pulmonary disease; Acute exacerbation; Serum thyroid hormone; Pronosis

引用本文: 程洋, 戴丽, 夏国光, 张运剑. 血清甲状腺激素水平对慢性阻塞性肺疾病急性加重患者预后评估价值研究. 中国呼吸与危重监护杂志, 2018, 17(4): 323-326. doi: 10.7507/1671-6205.201801064 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. 慢性阻塞性肺疾病急性加重 (AECOPD) 诊治专家组. 慢性阻塞性肺疾病急性加重 (AECOPD) 诊治中国专家共识 (2017 年修订版). 国际呼吸杂志, 2017, 37(14): 1041-1057.
2. Edwards L, Perrin K, Wijesinghe M, et al. The value of the CRB65 score to predict mortality in exacerbations of COPD requiring hospital admission. Respirology, 2011, 16(4): 625-629.
3. Global Initiative for Chronic Obstructive Lung Disease(GOLD): Global Strategy for the Diagnosis, Management and Prevention of Chronic Pulmonary Disease(2017 REPORT). http://www.goldcopd.org.
4. Hennemann G, Krenning EP. The kinetics of thyroid hormone transporters and their role in non-thyroidal illness and starvation. Best Pract Res Clin Endocrino Metab, 2007, 21(2): 323-338.
5. Plikat K, Langgartner J, Buettner R,et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism, 2007, 56(2): 239-244.
6. Sahana PK, Ghosh A, Mukhopadhyay P, et al. A study on endocrine changes in patients in intensive care unit[J]. J Indian Med Assoc, 2008, 106(6): 362-364.
7. Adler SM, Wartofsky L. The nonthyroidal illness syndrome. Endocrinol Metab Clin North Am, 2007, 36(3): 657-672.
8. 高绪文, 李继莲. 甲状腺疾病. 北京: 人民卫生出版社, 1999, 157-158.
9. 俞春娟, 和明丽, 王俊军, 等. 慢性阻塞性肺疾病急性加重期低 T3 综合征及其临床意义. 上海医药, 2014, 35(17): 34-37.
10. 程洋, 戴丽, 夏国光. 慢性阻塞性肺疾病急性加重患者血清甲状腺激素水平变化及临床意义. 中华结核和呼吸杂志, 2016, 39 (12): 939-943.
11. 程洋, 戴丽, 张运剑, 等. 慢性阻塞性肺疾病急性加重期患者血清甲状腺激素水平与疾病严重程度的相关性. 中国医药, 2017, 12(6): 855-857.
12. 周清, 吴琦. 老年 COPD 患者肺功能与血清甲状腺激素的相关性分析. 山东医药, 2012, 52(12): 92-94.
13. 罗洁, 王德明. 非甲状腺疾病综合征对危重症患者的影响. 中国实用医药, 2010, 5(36): 247-248.
14. 吴红花, 高燕明. 老年病与正常甲状腺病态综合征. 中华老年多器官疾病杂志, 2011, 10(6): 570-572.
15. 余松林. 医学统计学. 北京: 人民卫生出版社, 2002, 164-178.